Skip to content
Back to Blog
Bio
2026-09-297 min read11

US Section 232 Pharmaceutical Tariffs Take Effect Sept 29 — Korea Named a Zero-Tariff Eligible Jurisdiction: What Separates 0% (ADC, CGT, Orphan Drugs) from 15% Products, and a Checklist for Bio SME Exporters

US Section 232 pharmaceutical tariffs reach SMEs and mid-sized exporters on September 29, and Korea is one of 19 zero-tariff eligible jurisdictions. This guide explains what separates 0% products (ADCs, cell and gene therapies, orphan drugs) from 15% products and lists five checks for bio SME exporters.

KITIM Consulting Team

What's Now Final — From the April Proclamation to the September BIS Guidance

As of today, September 29, US Section 232 tariffs on pharmaceuticals apply to small and mid-sized exporters too. Here is how the past six months unfolded.

  • Early April 2026 announcement: Patented drugs and their ingredients face tariffs of up to 100% in principle, with a 15% cap for trade-deal partners including Korea, the EU and Japan.
  • Generics and biosimilars, along with their ingredients, are excluded from the tariffs for now, and the Secretary of Commerce must report to the President within one year of the proclamation (by April 2027) on whether action is needed. This is a provisional exclusion subject to review, not a fixed one-year deferral.
  • Timing: Certain large companies have been covered since July 31. Everyone else is covered from September 29, 180 days after the announcement, so for SMEs and mid-sized exporters the tariffs apply from this week.
  • BIS guidance: On September 23 (US time), the Commerce Department's Bureau of Industry and Security published implementing guidance for Presidential Proclamation 11020 in the Federal Register. It lists Korea among 19 "zero-tariff eligible jurisdictions," alongside the EU, Japan, the UK, Switzerland, India and Taiwan.
  • Which Products Qualify for 0%, and the Practical Test

    Being an eligible jurisdiction does not make every product duty-free. The 0% rate covers only these categories:

  • Drugs whose approved indications are all rare diseases
  • Radiopharmaceuticals, plasma-derived products and fertility treatments
  • Cell and gene therapies and antibody-drug conjugates (ADCs)
  • CBRN medical countermeasures and veterinary medicines
  • The Orphan Drug Trap: "All Indications"

    Having a single rare-disease indication may not be enough. The test covers all approved indications, so expanding into a common disease could change how the product is classified. When you plan an indication expansion, weigh the tariff impact next to pricing and market size.

    Where 15% Still Applies

    Patented prescription drugs and their ingredients outside the eligible categories stay at 15%. Reclassify your US export portfolio category by category. News reports describe the rules in slightly different ways, so check the final wording against the Federal Register text and the HTS classification used at customs.

    Five Things Bio SME Exporters Should Check Now

  • Build a product-level tariff map: Separate finished products, APIs and intermediates (ADC linkers and payloads, CGT starting materials and so on), and confirm the rate for each. A finished product in a 0% category does not guarantee the same treatment for its intermediates.
  • Plan scenarios for generics and biosimilars: Get ready for the review the Secretary of Commerce must report on by April 2027. Prepare pricing and contract terms for both a 0% and a 15% outcome.
  • Update contracts and origin documents: Review the Incoterms and duty-allocation clauses with US partners and distributors, and put your certificate-of-origin paperwork in order.
  • Use the CDMO opening: Sponsors now have a reason to prefer manufacturing in eligible jurisdictions. This overlaps with demand to replace Chinese suppliers under the BIOSECURE Act, so it is worth stating "eligible-jurisdiction manufacturing" explicitly in your proposals.
  • Compare restructuring costs: For products still facing 15%, compare that duty against the cost of US manufacturing or out-licensing.
  • Connecting to Government Support

  • Trade support channels: Tariff-response export vouchers, trade insurance and KOTRA trade advisory services can lower the cost of classification advice and contract renegotiation.
  • Pair with regulatory programs: Combining these with global regulatory support programs such as K-VIP lets you design your FDA approval strategy and tariff strategy together. Check the current year's program notice for eligibility and deadlines.
  • Prepare with KITIM

    The Korea Institute of Technology Innovation Management (KITIM) supports tariff classification reviews for US-bound products, combined analysis of indication and formulation strategy alongside tariff exposure, and applications for export voucher and regulatory support programs. If you need to know how today's tariffs affect your products, request a consultation through the KITIM contact page. Our consultants will work with you on a product-by-product checklist and a response plan.

    US Pharmaceutical TariffsSection 232Zero-Tariff Eligible JurisdictionADCCell and Gene TherapyOrphan DrugsBiosimilar Tariff ExemptionBio Export

    Related Posts

    Bio

    Biologics Approval Fees Rise From KRW 8.03M to 20.71M, Data-Submission Drugs About 6x — MFDS Fee Regulation Amendment Pre-Announced Nov 6, 2026 (Comments Due Nov 26 / Dec 16): Filing Timing, Budget Review and Fee-Reduction Checks for Pharma & Bio SMEs

    Under the fee amendment MFDS proposed on November 6, approval fees for new biologics would rise from KRW 8.03 million to KRW 20.71 million, and fees for data-submission drugs would go up about sixfold. This guide shows pharma and bio SMEs how to review their filing timing, budgets, fee-reduction eligibility and public comments.

    2026-11-09
    Management Consulting

    Factories With 20–49 Workers Will Need a Safety or Health Manager — Korea's First Tripartite Agreement on November 5 (About 30,000 Sites in 5 Industries Including Manufacturing, Decree Amendment in 2027, Target Start 2028), the Owner-Led Alternative and Government Payroll Support: A Preparation Guide for Small Manufacturers

    Under Korea's November 5 tripartite agreement, about 30,000 sites with 20–49 workers in manufacturing and four other industries are expected to need a qualified safety or health manager from 2028. This guide covers what is settled and what is still open, the owner-led alternative, a cost comparison, and a preparation checklist.

    2026-11-09
    Government Programs

    SMEs Can Now Enter the KRW 1,500 Trillion 'Mega Project' Supply Chain from the Design Stage — MSS Joins as a Lead Ministry, Large/Mid-Tier–SME Councils and Regional Councils Launch (Nov 6 Plan to Expand Planning-Stage Participation), and How SMEs Targeting Semiconductor, AI Data Center and Physical AI Supply Chains Should Prepare Validation, Certification and Mass-Production Qualification

    MSS has joined Korea's KRW 1,500 trillion mega projects as a lead ministry and plans to bring SMEs in from the planning stage. This guide covers how the central and regional councils will work and how to line up support programs against the validation, certification and mass-production barriers.

    2026-11-09
    Updated daily

    Let AI find government support programs in this field

    Complete a 3-minute company assessment and we will recommend programs that fit your company, each with a match score. It is free.

    Get AI-Matched Programs for Free

    Need Consulting?

    Our technology innovation consultants will propose the optimal solution for your company.